-
公开(公告)号：US20090208945A1
公开(公告)日：2009-08-20
申请号：US12097961
申请日：2006-12-19
申请人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
发明人： Stephan Schwers , Udo Stropp , Harald Kallabis , Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Gerd Schmitz
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/42 , C12Q1/50 , C12Q2600/106 , C12Q2600/156 , C12Q2600/172 , G01N33/92
摘要： The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence.
摘要翻译： 本发明提供了包括寡核苷酸和/或多核苷酸或衍生物的诊断方法和试剂盒，包括确定人类受试者在他汀类药物治疗后是否存在药物反应不利的风险的抗体。 本发明还提供了多态序列和其他基因。 本发明还涉及编码SADR基因多肽的分离的多核苷酸，其用于鉴定治疗剂并可用于制备治疗他汀类药物诱导的不良药物反应（SADR）的药物的方法中，所述多核苷酸选自SEQ ID No.1 -35具有等位基因变异，如包含在功能性周围的序列部分中所示，如SADR基因多肽的全长cDNA并具有或不具有SADR基因启动子序列。
-
公开(公告)号：US20090093689A1
公开(公告)日：2009-04-09
申请号：US12158744
申请日：2006-12-11
申请人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
发明人： Andreas Schuppert , Rolf Burghaus , Christian Von Torne , Stephan Schwers , Udo Stropp , Harald Kallabis
摘要： The invention relates to a method for developing a biomarker for the prognosis of the result of a therapeutical treatment based on data obtained in clinical studies, data remaining unchanged by therapy being subdivided into diagnostic and genomic parameters and the marker being defined by a combination of parameters. The method according to the invention is characterized by specifying the maximum number of parameters for defining the marker and thus the maximum complexity of the system from the beginning and by carrying out the search for defining parameters by sequential combination of clinical parameters (=z parameters) and/or genomic parameters (=x parameters).
摘要翻译： 本发明涉及一种基于临床研究中获得的数据，用于预测治疗结果的预后的生物标志物的方法，通过治疗将其保持不变的数据被细分为诊断和基因组参数，并且所述标记由参数的组合定义 。 根据本发明的方法的特征在于指定用于定义标记的参数的最大数目，并且因此指定从一开始的系统的最大复杂度，并且通过临时参数（= z参数）的顺序组合执行定义参数的搜索， 和/或基因组参数（= x参数）。
-
公开(公告)号：US20090130678A1
公开(公告)日：2009-05-21
申请号：US12095922
申请日：2006-11-23
IPC分类号： C12Q1/68 , C12Q1/02 , G01N33/574 , C40B30/00
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , G01N2333/91215
摘要： The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient.
摘要翻译： 本发明涉及患者中增殖性疾病的预后领域。 更具体地，本发明涉及用于鉴定乳腺癌患者乳腺癌的可能结果的方法。 本发明还涉及基于患者的ERBB2状态和所述患者的肿瘤组织中的免疫基因的表达水平来鉴定患者中乳腺癌的可能结果的方法。
-
-
搜索结果
3 条记录 (耗时 0.023 秒)
